Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Sep 17, 2024 - 22:57

0 5

The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

According to The Business Research Company’s Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Global Market Report 2024, The sodium glucose cotransporter 2 (SGLT2) inhibitors market size has grown strongly in recent years. It will grow from $9.37 billion in 2023 to $10.17 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to early clinical trial successes, rising regulatory approvals, increasing diabetes diagnosis rates, and the demand for innovative diabetes treatments.

The sodium glucose cotransporter 2 (SGLT2) inhibitors market size is expected to see strong growth in the next few years. It will grow to $14.19 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing obesity rates, growing awareness of diabetes management, and expanding applications in heart and kidney disease treatments. Major trends in the forecast period include the integration of combination therapies, personalized medicine approaches, technological improvement, and traditional drug development.

The increasing prevalence of diabetes is expected to propel the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market going forward. Diabetes refers to a group of metabolic disorders characterized by high blood sugar levels resulting from defects in insulin secretion, insulin action, or both. The rise in diabetes cases can be attributed to factors such as urbanization, stress, environmental pollutants, and a lack of access to healthcare services. Sodium glucose cotransporter 2 (SGLT2) inhibitors are used in diabetes treatment to lower blood glucose levels by preventing glucose reabsorption in the kidneys, leading to its excretion in urine. They also offer cardiovascular and renal benefits, making them a valuable option for managing diabetes and its complications. For instance, in July 2021, according to the International Diabetes Federation, a Belgium-based national diabetes association, the total number of people living with diabetes is expected to increase to 643 million by 2030 and 783 million by 2045. Three out of four adults with diabetes reside in low- and middle-income countries. Therefore, the increasing prevalence of diabetes is driving the growth of the sodium glucose cotransporter 2 (SGLT2) inhibitor market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

The sodium glucose cotransporter 2 (SGLT2) inhibitors market covered in this report is segmented –

1) By Type: Invokana, Jardiance, Farxiga Or Forxiga, Suglat
2) By Route Of Administration: Oral Route, Other Route Of Administration
3) By End User: Hospitals, Homecare Settings, Clinics

Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitor market are focused on developing dual inhibitor therapeutic solutions to improve patient outcomes and manage blood sugar levels. Dual inhibitor therapeutic solutions refer to treatments that simultaneously target two different sodium-glucose cotransporters (SGLT1 and SGLT2) to enhance efficacy in managing conditions such as heart failure and diabetes. For instance, in May 2023, Lexicon Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the Food and Drug Administration (FDA) for sotagliflozin, a treatment for heart failure. This first-in-class dual inhibitor of sodium-glucose cotransporters 1 and 2 is a once-daily tablet designed to reduce cardiovascular death, heart failure hospitalizations, and urgent heart failure visits in adults with heart failure, type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Its benefits include reduced renal glucose and sodium reabsorption, which leads to preload and afterload reduction and decreased sympathetic activity.

The sodium glucose cotransporter 2 (sglt2) inhibitors market report table of contents includes:

1. Executive Summary

2. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Characteristics

3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Trends And Strategies

4. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market - Macro Economic Scenario

5. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size and Growth
............

32. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Benchmarking

33. Global Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market

35. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Future Outlook and Potential Analysis

36. Appendix

Contact Us: